{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:27:41Z","timestamp":1790724461765,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Health@InnoHK"},{"DOI":"10.13039\/501100003452","name":"Innovation and Technology Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003452","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Government of the Hong Kong Special Administrative Region of the People\u2019s Republic of China"},{"name":"National Program on Key Research Project of China","award":["2020YFA0707500"],"award-info":[{"award-number":["2020YFA0707500"]}]},{"name":"National Program on Key Research Project of China","award":["2020YFA0707504"],"award-info":[{"award-number":["2020YFA0707504"]}]},{"name":"Theme-Based Research Scheme","award":["T11\/707\/15"],"award-info":[{"award-number":["T11\/707\/15"]}]},{"name":"Research Grants Council, Hong Kong Special Administrative Region; and the High Level-Hospital Program"},{"name":"Health Commission of Guangdong Province, China"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.phrs.2020.104960","type":"journal-article","created":{"date-parts":[[2020,5,27]],"date-time":"2020-05-27T22:14:36Z","timestamp":1590617676000},"page":"104960","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"special_numbering":"C","title":["Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system"],"prefix":"10.1016","volume":"159","author":[{"given":"Shuofeng","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper F.W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenn K.H.","family":"Chik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris C.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica O.L.","family":"Tsang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronghui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianli","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Lei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Piao","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zi-Wei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hin","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwok-Yung","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.104960_bib0005","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.tim.2013.05.005","article-title":"Interspecies transmission and emergence of novel viruses: lessons from bats and birds","volume":"21","author":"Chan","year":"2013","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.phrs.2020.104960_bib0010","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1128\/CMR.00023-07","article-title":"Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection","volume":"20","author":"Cheng","year":"2007","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.phrs.2020.104960_bib0015","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/CMR.00102-14","article-title":"Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease","volume":"28","author":"Chan","year":"2015","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.phrs.2020.104960_bib0020","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus from Patients with Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104960_bib0025","series-title":"Coronavirus Disease 2019 (COVID-19) Situation Report \u2013 77","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.phrs.2020.104960_bib0030","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0140-6736(20)30154-9","article-title":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster","volume":"395","author":"Chan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.104960_bib0035","first-page":"ciaa198","article-title":"A Case Series of children with 2019 novel coronavirus infection: clinical and epidemiological features","author":"Cai","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2020.104960_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(20)30243-7","article-title":"Estimates of the severity of coronavirus disease 2019: a model-based analysis","author":"Verity","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.phrs.2020.104960_bib0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"Guan","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104960_bib0050","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2020.104960_bib0055","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrd.2015.37","article-title":"Coronaviruses - drug discovery and therapeutic options","volume":"15","author":"Zumla","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.phrs.2020.104960_bib0060","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.phrs.2020.104960_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.phrs.2020.104960_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2020.104960_bib0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104787","article-title":"The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro","author":"Caly","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.phrs.2020.104960_bib0080","first-page":"ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2020.104960_bib0085","doi-asserted-by":"crossref","DOI":"10.1016\/S2666-5247(20)30004-5","article-title":"An observational study on the comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV: implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19","author":"Chu","year":"2020","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.phrs.2020.104960_bib0090","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.104960_bib0095","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1093\/infdis\/jit123","article-title":"Differential cell line susceptibility to the emerging novel human betacoronavirus 2c EMC\/2012: implications for disease pathogenesis and clinical manifestation","volume":"207","author":"Chan","year":"2013","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phrs.2020.104960_bib0100","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciaa410","article-title":"Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19","author":"Chu","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2020.104960_bib0105","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/s41467-018-08015-x","article-title":"SREBP-dependent lipidomic reprogramming as a broad-spectrum antiviral target","volume":"10","author":"Yuan","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2020.104960_bib0110","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1086\/430355","article-title":"Antigenic cross-reactivity between severe acute respiratory syndrome-associated coronavirus and human coronaviruses 229E and OC43","volume":"191","author":"Che","year":"2005","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.phrs.2020.104960_bib0115","first-page":"ciaa325","article-title":"Simulation of the clinical and pathological manifestations of Coronavirus Disease 2019 (COVID-19) in golden Syrian hamster model: implications for disease pathogenesis and transmissibility","author":"Chan","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.phrs.2020.104960_bib0120","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"key":"10.1016\/j.phrs.2020.104960_bib0125","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.antiviral.2015.11.005","article-title":"Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase","volume":"125","author":"Yuan","year":"2016","journal-title":"Antiviral Res."},{"key":"10.1016\/j.phrs.2020.104960_bib0130","doi-asserted-by":"crossref","DOI":"10.1128\/JCM.00310-20","article-title":"Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp\/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens","author":"Chan","year":"2020","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.phrs.2020.104960_bib0135","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1093\/jac\/dkw194","article-title":"A novel small-molecule compound disrupts influenza A virus PB2 cap-binding and inhibits viral replication","volume":"71","author":"Yuan","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.phrs.2020.104960_bib0140","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1365-2125.2008.03311.x","article-title":"Reduction of dietary fat absorption by the novel gastrointestinal lipase inhibitor cetilistat in healthy volunteers","volume":"67","author":"Bryson","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104960_bib0145","first-page":"33","article-title":"The treatment of amoebiasis with diodoquin","volume":"52","author":"Rickards","year":"1949","journal-title":"J. Trop. Med. Hyg."},{"key":"10.1016\/j.phrs.2020.104960_bib0150","first-page":"414","article-title":"Cetilistat, a new lipase inhibitor for the treatment of obesity","volume":"9","author":"Padwal","year":"2008","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"10.1016\/j.phrs.2020.104960_bib0155","article-title":"Gastrointestinal manifestations of SARS-CoV-2 infection and virus load in fecal samples from the Hong Kong cohort and systematic review and meta-analysis","author":"Cheung","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.104960_bib0160","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3201\/eid1009.040058","article-title":"Viral loads in clinical specimens and SARS manifestations","volume":"10","author":"Hung","year":"2004","journal-title":"Emerg Infect Dis."},{"key":"10.1016\/j.phrs.2020.104960_bib0165","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/S0960-0760(03)00078-5","article-title":") In vitro and in vivo models for the evaluation of potent inhibitors of male rat 17alpha-hydroxylase\/C17,20-lyase","volume":"84","author":"Duc","year":"2003","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"10.1016\/j.phrs.2020.104960_bib0170","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00280-019-03862-x","article-title":"Inter- and intra-patient variability in pharmacokinetics of abiraterone acetate in metastatic prostate cancer","volume":"84","author":"Arasaratnam","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.phrs.2020.104960_bib0175","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1021\/jm00016a018","article-title":"Design and synthesis of potent retinoid X receptor selective ligands that induce apoptosis in leukemia cells","volume":"38","author":"Boehm","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.phrs.2020.104960_bib0180","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1365-2133.2007.07975.x","article-title":"The optimal use of bexarotene in cutaneous T-cell lymphoma","volume":"157","author":"Gniadecki","year":"2007","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2020.104960_bib0185","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1158\/1078-0432.CCR-06-1836","article-title":"A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer","volume":"13","author":"Dragnev","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2020.104960_bib0190","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1200\/JCO.2003.05.068","article-title":"Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer","volume":"21","author":"Esteva","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2020.104960_bib0195","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1158\/1078-0432.CCR-16-3083","article-title":"Clinically relevant concentrations of anticancer drugs: a guide for nonclinical studies","volume":"23","author":"Liston","year":"2017","journal-title":"Clin. Cancer Res."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820312688?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820312688?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:08:23Z","timestamp":1760911703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820312688"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":39,"alternative-id":["S1043661820312688"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104960","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.104960","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104960"}}